1-(4-氨基-苯基)-环丁烷甲腈 | 811803-25-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(4-氨基-苯基)-环丁烷甲腈
• 英文名称: 1-(4-aminophenyl)cyclobutanecarbonitrile
• 英文别名: 1-(4-aminophenyl)cyclobutane-1-carbonitrile
• CAS: 811803-25-5
• 化学式: C₁₁H₁₂N₂
• 分子量: 172.23
• InChiKey: HUTJERLCYVJZPZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2926909090

反应信息

• 作为反应物：
  描述：

  1-(4-氨基-苯基)-环丁烷甲腈 在 草酰氯 、 sodium methylate 、 溶剂黄146 、 1-丙基磷酸酐 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三乙胺 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 甲基叔丁基醚 、 乙酸乙酯 为溶剂， 反应 117.0h， 生成
  参考文献：
  名称：

  Exploratory Process Development of a Novel Diacylglycerol Acyltransferase-1 (DGAT-1) Inhibitor

  摘要：

  A practical large-scale synthesis was developed for 1, a DGAT-1 inhibitor, involving an aza-Michael reaction, amidation, Dieckman cyclization, and conjugate addition of cyanamide followed by cyclization, to form the fused 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5-one scaffold. The enabled process presented here substantially improved safety (in particular, due to eliminating a nitration step and optimizing a high-energy intermediate step), reproducibility, and scalability, resulting in delivery of a multikilogram quantity of the API with high purity. The controls of API quality and particle size were also discussed.

  DOI：

  10.1021/op400215h
• 作为产物：
  描述：

  对硝基苯乙腈 在 5%-palladium/activated carbon 、 四丁基溴化铵 、 氢气 、 potassium carbonate 作用下， 以 甲醇 、 丙酮 为溶剂， 55.0~60.0 ℃ 、344.75 kPa 条件下， 反应 23.0h， 生成 1-(4-氨基-苯基)-环丁烷甲腈
  参考文献：
  名称：

  Exploratory Process Development of a Novel Diacylglycerol Acyltransferase-1 (DGAT-1) Inhibitor

  摘要：

  A practical large-scale synthesis was developed for 1, a DGAT-1 inhibitor, involving an aza-Michael reaction, amidation, Dieckman cyclization, and conjugate addition of cyanamide followed by cyclization, to form the fused 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5-one scaffold. The enabled process presented here substantially improved safety (in particular, due to eliminating a nitration step and optimizing a high-energy intermediate step), reproducibility, and scalability, resulting in delivery of a multikilogram quantity of the API with high purity. The controls of API quality and particle size were also discussed.

  DOI：

  10.1021/op400215h

文献信息

• 4-AMINO-7,8-DIHYDROPYRIDO[4,3-d]PYRIMIDIN-5(6H)-ONE DERIVATIVES
  申请人：Aspnes Gary E.

  公开号：US20100197591A1

  公开（公告）日：2010-08-05

  The invention provides compounds of the general Formula (I) where R 1 , R 2 , and A are defined herein, as well as the preparation, compositions and uses thereof.

  这项发明提供了一般式（I）的化合物 其中R1、R2和A在此处定义，以及其制备、组成和用途。
• NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS
  申请人：Alexander Christopher W.

  公开号：US20100144722A1

  公开（公告）日：2010-06-10

  Novel heterocyclic compounds, sstereoisomers thereof and/or pharmaceutically acceptable salts of formula (I) and its stereoisomers are provided. Additionally, methods of forming novel heterocyclic compounds, stereoisomers thereof and/or pharmaceutically acceptable salts of formula (I) and its stereoisomers are provided.

  提供了式(I)及其立体异构体和/或药学上可接受的盐的新型杂环化合物。此外，还提供了形成新型杂环化合物、其立体异构体和/或药学上可接受的盐的方法。
• Pyridyl Radical Cation for C−H Amination of Arenes
  作者：Simon L. Rössler、Benson J. Jelier、Pascal F. Tripet、Andrej Shemet、Gunnar Jeschke、Antonio Togni、Erick M. Carreira

  DOI：10.1002/anie.201810261

  日期：2019.1.8

  and unprecedented N‐pyridyl radical cation from selected N‐substituted pyridinium reagents. The resulting C(sp2)−H functionalization of (hetero)arenes furnishes versatile intermediates for the development of valuable aminated aryl scaffolds. Mechanistic studies that include the first spectroscopic evidence of a spin‐trapped N‐pyridyl radical adduct implicate SET‐triggered, pseudo‐mesolytic cleavage

  电子转移光催化使人们可以从选定的N-取代的吡啶鎓试剂中获得难以捉摸的N-吡啶基自由基阳离子。所得的（杂）芳烃的C（sp 2）-H功能化为开发有价值的胺化芳基骨架提供了多种中间体。包括第一个光谱学证据的自旋捕获的N-吡啶基自由基加合物的机理研究表明，SET触发了由可见光介导的N-X吡啶鎓试剂的伪介观裂解。
• Six membered amino-amide derivatives an angiogenisis inhibitors
  申请人：——

  公开号：US20040259916A1

  公开（公告）日：2004-12-23

  The present invention relates to six membered amino-amide derivatives, processes for their preparation, pharmaceutical compositions containing them as active ingredient, methods for the treatment of disease states associated with angiogenesis and/or increased vascular permeability, to their use as medicaments and to their use in the manufacture of medicaments for use in the production of antiangiogenic and/or vascular permeability reducing effects in warm-blooded animals such as humans.

  本发明涉及六元氨基酰胺衍生物，其制备方法，含有其作为活性成分的药物组合物，用于治疗与血管生成和/或增加血管通透性相关的疾病状态的方法，以及它们作为药物的用途以及在制造用于在温血动物（如人类）中产生抗血管生成和/或血管通透性降低作用的药物的用途。
• Novel Biccyclic Compounds As GATA Modulators
  申请人：De Dibyendu

  公开号：US20100144731A1

  公开（公告）日：2010-06-10

  Novel bicyclic compounds, stereoisomers, and/or pharmaceutically acceptable salts of the novel bicyclic compounds, and/or pharmaceutically acceptable salts of the stereoisomers of the novel bicyclic compounds are provided. Additionally, methods of forming novel bicyclic compounds, stereoisomers, and/or pharmaceutically acceptable salts of the novel bicyclic compounds, and/or pharmaceutically acceptable salts of the stereoisomers of the novel bicyclic compounds are provided.

  提供了新型双环化合物、立体异构体和/或新型双环化合物的药用可接受盐，以及新型双环化合物的立体异构体的药用可接受盐。此外，还提供了形成新型双环化合物、立体异构体和/或新型双环化合物的药用可接受盐，以及新型双环化合物的立体异构体的药用可接受盐的方法。